Low-Dose Rapamycin (Longevity Protocol)

Sirolimus (low-dose intermittent)

Low-dose intermittent rapamycin is the off-label longevity protocol popularized by Mikhail Blagosklonny and Peter Attia. Weekly doses of 3-6 mg are hypothesized to capture mTORC1 inhibition benefits while sparing mTORC2. Clearly experimental - not FDA-approved for longevity and not proven to extend human lifespan.

mTORC1 inhibitor (intermittent low-dose protocol)Prescription requiredEvidence speculative

⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.

Why it matters

The low-dose rapamycin protocol is the most discussed longevity intervention in geroscience-aware medicine, yet it sits firmly in experimental territory. The hypothesis: mouse lifespan extension is reproducible across the NIA ITP program, mTORC1 inhibition is mechanistically conserved, and intermittent low dosing should retain longevity-relevant benefits while avoiding the metabolic and immune costs seen in transplant patients. Mannick et al. showed that TORC1 inhibition improved vaccine response in older adults, suggesting immunosenescence is reversible at sub-transplant doses. Blagosklonny argued that rapamycin should be considered a population-level anti-aging intervention. Peter Attia incorporates weekly dosing in his clinical practice with extensive biomarker monitoring. Despite this, no randomized controlled trial has demonstrated human lifespan or healthspan extension. The PEARL trial is currently evaluating safety and biomarker effects in healthy adults. The protocol therefore requires physician supervision, biomarker monitoring (lipids, glucose, immune markers), and patient acceptance of an explicitly experimental intervention. Men considering this should treat it as participation in pre-clinical translation - not a proven longevity therapy.

Uses

Off-label (educational only)

General longevity and healthspan extension — Theoretical extrapolation from mouse ITP data plus Mannick immunosenescence trials; no randomized human longevity outcome trials exist
Periodic mTORC1 modulation in metabolically healthy adults — Aims to preserve insulin sensitivity and immune function relative to chronic dosing

Dosing

Label dose

Not FDA-approved for longevity. No label dose for this indication.

Off-label / biohacker dose

Common protocols: 3-6 mg orally once weekly; some clinicians use 5 mg every 10-14 days; cycling (e.g., 3 months on / 1 month off) is common. Doses are individualized and lack consensus.

Titration: Start at the lowest dose (3 mg weekly) and titrate based on tolerance and biomarker response. Monitor lipids, glucose/insulin, CBC every 3-6 months. Hold for infections, before surgery, and during pregnancy planning. Avoid grapefruit. This is an experimental, off-label, physician-supervised protocol - not a self-administered supplement.

When to take: Same day each week, on an empty stomach (consistent fat intake), grapefruit avoided. Some clinicians dose in the evening; others in the morning.

Side effects & warnings

Common

Mild stomatitis (uncommon at low doses)
Slight LDL-C or triglyceride rise
Occasional mild fatigue the day after dosing
Acne-like rash (uncommon)

Uncommon but serious

Insulin resistance (mild, dose-dependent)
Infection susceptibility (smaller signal than transplant dosing)
Delayed wound healing
Mouth ulcers if dose too high

Serious warnings

Even at low doses, rapamycin is an immunomodulator. Hold for active infection, before elective surgery (2-3 weeks), and avoid in pregnancy or breastfeeding. Pneumonitis remains a class-specific concern; new respiratory symptoms warrant evaluation. Outcomes data in healthy adults using this protocol do not yet exist.

Biomarkers affected

fasting glucose

variable

Intermittent dosing intended to spare mTORC2-mediated insulin signaling; clinical data limited

Evidence: anecdotal

hscrp

variable

Theoretical anti-inflammatory benefit via autophagy; no controlled human hsCRP outcome data

Evidence: anecdotal

igf 1

variable

mTORC1 inhibition may modestly reduce IGF-1; weekly dosing effect size unclear

Evidence: anecdotal

ldl c

variable

Modest LDL-C elevation possible; smaller magnitude than continuous dosing

Evidence: weak

triglycerides

variable

Smaller triglyceride rise than daily dosing; data from observational longevity cohorts and PEARL pending

Evidence: weak

Monitoring

Lipid panel, fasting glucose/insulin, HbA1c, CBC, ALT/AST, urinalysis at baseline and every 3-6 months. ApoB monitoring recommended; consider concurrent statin if LDL-C rises.

The honest risk picture

Even at low intermittent doses, rapamycin remains an immunomodulator. Mouth ulcers (stomatitis) are the most common side effect; dose reduction usually resolves them. Lipid effects exist even at low dose: modest triglyceride and LDL-C increases are typical and should be tracked, often with concurrent statin therapy in longevity practice. Mild insulin resistance can occur; HbA1c and fasting insulin should be monitored. Infection risk is reduced relative to transplant dosing but not eliminated - hold the drug for active infections, dental procedures with significant tissue trauma, and 2-3 weeks before and after elective surgery. Pneumonitis is a class-specific serious risk, regardless of dose; new respiratory symptoms warrant immediate evaluation. Avoid grapefruit and strong CYP3A4 inhibitors. Pregnancy, breastfeeding, and active malignancy are contraindications. Critically, no long-term outcome data in healthy adults using this protocol exist - users are participating in pre-clinical translation, not a proven therapy. The protocol should be undertaken only with physician supervision, regular biomarker monitoring, and informed consent regarding the experimental nature of the intervention.

Practical context

Cost (US, retail)

$300/mo

Legality

NOT FDA-approved for longevity or healthspan. Legal to prescribe off-label in the US under physician supervision. Use outside clinical supervision is discouraged. Experimental and unproven for human lifespan extension.

Interactions

true

FAQ

Is this approved for longevity?+

No. Rapamycin is FDA-approved only for organ transplant rejection prophylaxis and lymphangioleiomyomatosis. All longevity use is off-label and experimental. No randomized trial has shown human lifespan extension.

How is this different from standard rapamycin dosing?+

Standard transplant dosing is 2 mg daily, targeting continuous mTORC1 and mTORC2 suppression. The longevity protocol uses intermittent low doses (3-6 mg weekly) intended to inhibit mTORC1 while sparing mTORC2 - in theory preserving insulin sensitivity and immune function.

Should I take rapamycin?+

This is a decision to make with a physician experienced in the off-label longevity application. It is not a supplement or self-administered intervention. Outcomes data in healthy adults remain limited.

References (6)+

The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.